Darmstadt, Germany (ots/PRNewswire) - Not intended for UK- or UK-based media - Grant established by Merck recognizes pioneering research in personalized treatment of solid tumors - Winners selected by internationally renowned oncologists from 405 applications representing 49 countries Merck, a leading science and technology company, today announced the recipients of ...
Lugano, Switzerland (ots/PRNewswire) - ~ Helsinn Group creates new investment fund in 40th anniversary year ~ ~ The new fund will focus on supporting early-stage investment opportunities in areas of high unmet patient need ~ Helsinn, the Swiss Pharmaceutical Group focused on building quality cancer care, today introduces Helsinn Investment Fund S.A. ("the Fund"), a fund focused on early-stage investment opportunities in ...
Rheinfelden, Switzerland (ots/PRNewswire) - Zeria Pharmaceutical Co., Ltd. has received the approval for a new drug application for Zentacort 3mg capsules from the Ministry of Health, Labour and Welfare (MHLW) in Japan for the indication of the improvement of Crohn's Disease (CD). Following the acquisition of the ...
Paris and Singapore (ots/PRNewswire) - Cancer researchers from Assistance Publique - Hôpitaux de Paris (AP-HP) and The Asia-Pacific Hepatocellular Carcinoma Trials Group (AHCC), National Cancer Centre Singapore (NCCS) and Singapore Clinical Research Institute (SCRI) announced that they will collaborate on a ...
Shire Pharmaceuticals Group Plc
Lexington, Massachusetts (ots/PRNewswire) - Shire plc (LSE: SHP, NASDAQ: SHPG) announced today that the U.S. Patent & Trademark Office's Patent Trial and Appeal Board (PTAB) has issued their decision upholding the validity of U.S. Patent No. 6,773,720, related to Shire's LIALDA® (mesalamine) product. The petition seeking to institute inter partes review (IPR) was ...
London (ots/PRNewswire) - Following the acquisitions of Invent Farma and neuraxpharm (the "Group") by funds advised by Apax Partners, Stephan Walz has been appointed Chief Executive Officer. He will assume the newly-created role of Group CEO and will be leading Invent Farma's and neuraxpharm's activities across all markets. Until 2015 Mr Walz was the CEO of Aristo, a Germany-headquartered, multi-country pharmaceutical ...
Munich (ots/PRNewswire) - Results highlight the benefits of reduced dose edoxaban compared to warfarin in a potentially higher risk venous thromboembolism (VTE) patient population[1] Daiichi Sankyo Europe GmbH (hereafter Daiichi Sankyo) today announced data from a new analysis of the phase 3 Hokusai-VTE study, which ...
Teva Pharmaceutical Industries Ltd.
Amsterdam (ots/PRNewswire) - Approval of hybrid high-dose fluticasone/salmeterol maintenance treatment for people living with severe asthma and COPD, delivered via the award-winning Spiromax® inhaler to help patient usability Teva Pharmaceutical Industries Ltd., announced today that it has received EU Marketing Authorization for Aerivio Spiromax® ...
Nuremberg, Germany (ots/PRNewswire) - A recent international GfK survey (http://www.gfk.com/global-studies/global-study-overview/), conducted online in 16 countries, shows one in three people (33 percent) currently monitor or track their health or fitness via an online or mobile application, or via a fitness band, clip, or smartwatch. China is well in the lead for ...
Wessling (ots) - Dornier MedTech®, a global medical device company, introduced their latest innovation in laser lithotripsy. Known as the Dornier GentleFlex®, this is a specially-designed ball tip fiber. The Dornier GentleFlex® smooths the passage of the laser fiber through a deflected scope. The Dornier ...
Darmstadt, Germany (ots/PRNewswire) - Not intended for UK-based media ESMO Abstract # Avelumab: 777PD, 7775PD, 1154P, 842TiP, 844TiP; Erbitux: 527P, 491P, 967P, 994P; Tepotinib: 1257P, 1287TiP, 1292TiP - Merck KGaA, Darmstadt, Germany, to feature new research from marketed and pipeline compounds - Preliminary results from combination study with avelumab in renal cell ...
Darmstadt, Germany (ots/PRNewswire) - Not intended for UK- or US-based media ESMO Abstract # Avelumab: 777PD, 775PD, 1154P, 842TiP, 844TiP; Erbitux: 527P, 491P, 967P, 994P; Tepotinib: 1257P, 1287TiP, 1292TiP - Merck to feature new research from marketed and pipeline compounds - Preliminary results from combination study with avelumab in renal cell carcinoma, and ...
Darmstadt, Germany (ots/PRNewswire) - - New partnership under Healthy Women, Healthy Economies initiative facilitates women to overcome health barriers to economic participation Merck, a leading science and technology company, today announced its partnership with the Royal Health Awareness Society (RHAS) of Jordan to advance health awareness and education particularly ...
Bagsværd, Denmark (ots/PRNewswire) - This material is intended for global medical media only. For journalistic assessment and preparation before publication. Novo Nordisk today announced that the Committee for Medicinal Products for Human Use, CHMP, has adopted a positive opinion to extend the use of NovoRapid® (insulin aspart) in the European Union for children with ...
Darmstadt, Germany (ots/PRNewswire) - Not intended for UK-based media - Phase III studies highlight lasting reductions in relapse rates for an additional two years following short oral treatment courses in year one & year two with Cladribine Tablets Merck, a leading science and technology company, announced they ...
Munich (ots/PRNewswire) - This material is intended for global medical media only. For journalistic assessment and preparation before publication. Novo Nordisk today announced that semaglutide, an investigational glucagon-like peptide-1 (GLP-1) analogue administered once-weekly, significantly reduced the risk of the ...
Darmstadt, Germany (ots/PRNewswire) - - Four research grants awarded out of 260 proposals from 45 countries Merck, a leading science and technology company, today announced recipients of the fourth annual Grant for Multiple Sclerosis Innovation (GMSI) during a symposium at the 32nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis ...
Munich (ots/PRNewswire) - This material is intended for global medical media only. For journalistic assessment and preparation before publication. Novo Nordisk today announced that the progression of kidney damage was significantly lower with Victoza® treatment vs placebo, as measured by urinary albumin creatinine ratio, both added to standard of care in 9,340 adults ...
Paris (ots/PRNewswire) - Further comparative data expected from ongoing head-to-head clinical trial Sanofi (http://www.sanofi.com) announced today the key results of a new pharmacokinetic / pharmacodynamic (PK/PD) study in people with type 1 diabetes comparing Toujeo® (insulin glargine 300 Units/mL) to insulin ...
Munich (ots/PRNewswire) - This material is intended for global medical media only. For journalistic assessment and preparation before publication. Results from a post hoc analysis of the three-year part of the phase 3a SCALE (Satiety and Clinical Adiposity - Liraglutide Evidence) Obesity and Prediabetes trial show ...
Paris (ots/PRNewswire) - - Benefits on adherence and HbA1c to be validated in a real-world setting - Sanofi (http://www.sanofi.com) announced today that adults with type 2 diabetes treated with Toujeo® (insulin glargine 300 Units/mL) experienced a consistently lower rate of confirmed or severe hypoglycemia both at ...
Munich, Germany (ots/PRNewswire) - This material is intended for global medical media only. For journalistic assessment and preparation before publication. Novo Nordisk today presented data showing the odds of reaching fasting plasma glucose (FPG) targets without hypoglycaemia and weight gain were significantly ...
Munich (ots/PRNewswire) - This material is intended for global medical media only. For journalistic assessment and preparation before publication. Novo Nordisk today announced that semaglutide, an investigational glucagon-like peptide-1 (GLP-1) analogue administered once-weekly, significantly improved glycaemic ...
Darmstadt, Germany (ots/PRNewswire) - - Two oral presentations and nine posters include new analyses on investigational Cladribine Tablets - Real-world data assess the safety, tolerability and effectiveness of Rebif® - Symposium highlights unmet needs among patients with MS and real-word issues - Grant for Multiple ...
Verona, Italy (ots/PRNewswire) - CROMSOURCE, an international contract research organization (CRO) providing a comprehensive portfolio of services to the pharmaceutical, biotechnology, and medical device industries, announced today the appointment of its new Chief Medical Officer, Dr. Grzegorz Rychlik, and the expansion of its Medical Affairs Services department. ...
Amsterdam and London (ots/PRNewswire) - Philips to highlight the Dream Family connected therapy system, announcing its extension with the introduction of BiPAP autoSV and BiPAP AVAPS therapy devices Philips Respironics (http://www.respironics.com/), a division of Royal Philips (http://www.usa.philips.com/) (NYSE: ...
Munich (ots/PRNewswire) - Not for US or UK media - ENSURE-AF is the largest clinical trial of a non-vitamin K antagonist oral anticoagulant in patients with non-valvular atrial fibrillation - who undergo electrical cardioversion - ENSURE-AF is a Prospective, Randomized, Open-Label, Blinded E ndpoint evaluation ...
Calgary, Alberta (ots/PRNewswire) - The presentations at the ESC Congress symposium highlighted apabetalone and the opportunity and need for a novel approach to the treatment of high risk cardiovascular disease and diabetes. Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) today announced that on Sunday, ...
Shire Pharmaceuticals Group Plc
Lexington, Massachusetts (ots/PRNewswire) - - Xiidra is the only prescription eye drop approved by the U.S. FDA for the treatment of both signs and symptoms of dry eye disease - Resources are available to support patients seeking information regarding coverage and savings offers - Xiidra is the first medication in a ...
Munich (ots/PRNewswire) - Sub-analysis data from atrial fibrillation patient registry sponsored by Daiichi Sankyo reveals at-risk patient groups and recent trends in disease management[1],[2] Not for US media Daiichi Sankyo Europe GmbH (hereafter, Daiichi Sankyo) today announced data from new sub-analyses of the ...